CoMparison of TriflusAl and Clopidogrel Effect in Secondary Prevention of STroke Based on the CytochRome P450 2C19 GenOtyping; MAESTRO study
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0000025
- Lead Sponsor
- Yonsei University Health System, Gangnam Severance Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 1080
1. Patients who have non-caridogenic ischemic stroke of TOAST classification within 30 days prior to screening
2. = 20 years of age; adult, at the date of signing the informed consent
3. Written informed consent
1. History for bleeding tendency or recent major bleeding within 2 weeks
2. Chronic liver disease (ALT>100 or AST>100) or renal dysfunction (creatinine>4.0mg/dl)
3. Thrombocytopenia (platelet<100,000mm3)
4. Any contraindication of antiplatelet agent
5. Severe congestive heart failure
6. Patients who need to take anticoagulants or two more antiplatelet agents
7. Severe concomitant disease with the expected survival less than 2 years
8. Pregnant or nursing
9. Any drug clinical trials within 30 days of signing the informed consent
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method